TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer

Table 3

MINORS quality evaluation for included uncontrolled studies.

Study	Clear purpose	Patient continuity	Data collection	Appropriate endpoint	Objective evaluation endpoint	Adequate follow-up time	Low lost to follow-up rate	Sample size estimation	Total score
Cicero et al. 2020 [24]	2	2	2	2	1	2	1	0	12
Cecchini et al. 2021 [25]	2	2	2	2	1	2	0	0	11
Sforza et al. 2017 [26]	2	2	2	2	1	2	2	0	13
Montes et al. 2020 [27]	2	2	2	2	1	2	1	0	12
Takahashi et al. 2021 [28]	2	2	1	2	1	2	1	0	11
Kwakman et al. 2018 [29]	2	2	2	2	2	2	1	0	13
Moehler et al. 2021 [30]	2	2	1	2	1	1	2	0	11
Yoshida et al. 2020 [31]	2	2	2	2	2	2	2	1	15
Wallander et al. 2020 [32]	2	2	2	2	1	2	2	0	13
Satake et al. 2020 [33]	2	2	2	2	2	2	1	2	15
Carries et al. 2019 [34]	2	2	2	2	1	2	1	0	12